Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulias V, Mavroudis D. Karachaliou N, et al. Among authors: papadimitraki e. Cancer Chemother Pharmacol. 2012 Jul;70(1):169-76. doi: 10.1007/s00280-012-1901-3. Epub 2012 Jun 6. Cancer Chemother Pharmacol. 2012. PMID: 22669571 Clinical Trial.
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Koinis F, Polyzos A, Christopoulou A, Zafeiriou Z, Emmanouilidis C, Papadimitraki E, Kalykaki A, Kalbakis K, Samonis G, Georgoulias V. Koinis F, et al. Among authors: papadimitraki e. Cancer Chemother Pharmacol. 2014 Apr;73(4):819-25. doi: 10.1007/s00280-014-2411-2. Epub 2014 Feb 15. Cancer Chemother Pharmacol. 2014. PMID: 24531559 Clinical Trial.
Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
Vetsika EK, Papadimitraki E, Aggouraki D, Konsolakis G, Mela ME, Kotsakis A, Christou S, Patramani S, Alefantinou M, Kaskara A, Christophyllakis C, Kosmatopoulos K, Georgoulias V, Mavroudis D. Vetsika EK, et al. Among authors: papadimitraki e. J Immunother. 2011 Nov-Dec;34(9):641-50. doi: 10.1097/CJI.0b013e31823284a6. J Immunother. 2011. PMID: 21989412
Colovesical fistula demonstrated on renal cortical scintigraphy.
Stathaki M, Vamvakas L, Papadaki E, Papadimitraki E, Tsaroucha A, Karkavitsas N. Stathaki M, et al. Among authors: papadimitraki e. Clin Nucl Med. 2012 Nov;37(11):1112-4. doi: 10.1097/RLU.0b013e31826c0d27. Clin Nucl Med. 2012. PMID: 23047758
Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.
Kentepozidis N, Soultati A, Giassas S, Vardakis N, Kalykaki A, Kotsakis A, Papadimitraki E, Pantazopoulos N, Bozionellou V, Georgoulias V. Kentepozidis N, et al. Among authors: papadimitraki e. Cancer Chemother Pharmacol. 2012 Jul;70(1):161-8. doi: 10.1007/s00280-012-1896-9. Epub 2012 Jun 3. Cancer Chemother Pharmacol. 2012. PMID: 22660737 Clinical Trial.
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
Agelaki S, Kontopodis E, Kotsakis A, Chandrinos V, Bompolaki I, Zafeiriou Z, Papadimitraki E, Stoltidis D, Kalbakis K, Georgoulias V. Agelaki S, et al. Among authors: papadimitraki e. Cancer Chemother Pharmacol. 2013 Jul;72(1):45-51. doi: 10.1007/s00280-013-2167-0. Epub 2013 Apr 21. Cancer Chemother Pharmacol. 2013. PMID: 23604531 Clinical Trial.
45 results